Furuya Y, Yamamoto K, Kohno N, Yamamoto M, Saitoh Y
First Department of Surgery, Kobe University School of Medicine, Japan.
Cancer Lett. 1995 Aug 1;94(2):207-11. doi: 10.1016/0304-3835(95)03851-m.
Nocturnal infusion of 5-fluorouracil (FUra) was performed in nine patients with disseminated cancer. Three gastric, three colon and three breast cancer patients were administered 300 mg/m2 FUra continuously for 10 h per day from 2100 h to 0700 h for more than 20 consecutive days. In the first three patients, who were treated by drip infusion without the use of a volumetric pump, serum FUra concentrations ranged widely, from 27 to 130 ng/ml, even though the rate of administration was re-adjusted four times during the night. The last six patients were treated using a volumetric pump, and FUra concentrations in serum ranged from 175 to 378 ng/ml, and displayed no circadian rhythm. Although the dose intensity and area under the curve of FUra in these patients were high, neither myelosuppression nor other side effects were observed.
对9例播散性癌症患者进行了5-氟尿嘧啶（FUra）夜间输注。3例胃癌、3例结肠癌和3例乳腺癌患者，每天从21:00至07:00连续10小时给予300mg/m²FUra，持续20多天。在前3例通过滴注而非使用容量泵治疗的患者中，尽管夜间给药速率重新调整了4次，但血清FUra浓度仍在27至130ng/ml之间广泛波动。最后6例患者使用容量泵治疗，血清中FUra浓度在175至378ng/ml之间，且无昼夜节律。尽管这些患者中FUra的剂量强度和曲线下面积较高，但未观察到骨髓抑制或其他副作用。
